LEADING ARTICLE

Is intestinal metaplasia of the stomach reversible?

M M Walker

Intestinal metaplasia (IM) of the stomach is a risk factor in developing intestinal-type gastric cancer and hence the question of reversibility is vital. There is emerging epidemiological evidence that with long term follow up, IM may be reversible although a combination of antioxidant agents and eradication of *H pylori* may be necessary to achieve this. The pathogenesis of IM is currently being elucidated and it is likely that a combination of bacterial, host, and environmental factors will be shown to lead to IM. In assessing gastric cancer risk, histochemical typing of IM will most probably be replaced by molecular markers.

**SUMMARY**

As intestinal metaplasia (IM) of the stomach is a risk factor in developing intestinal-type gastric cancer, the question of reversibility is vital. The pathogenesis of gastric IM is being investigated and it is likely that a combination of genetic aspects of both *Helicobacter pylori* and the host, and also environmental factors will be shown to cause this precancerous condition. There is emerging epidemiological evidence that with long term follow up (at least five years after *H pylori* eradication) IM may be reversible. Abolition of *H pylori* alone may not be the answer and combination with other chemopreventive agents may be necessary. IM can be elusive and it is necessary to undertake careful endoscopic evaluation and biopsy likely sites (the lesser curve and angulus). In assessing gastric cancer risk, histochemical typing of IM will probably be replaced by molecular markers although neither of these at present provides a better cancer risk index than simple gastritis scores of antral and body mucosa and the mere presence of IM.

**IS INTESTINAL METAPLASIA OF THE STOMACH REVERSIBLE?**

It is of fundamental importance to answer this question—if IM of the stomach is reversible, therapeutic intervention may be possible but if not, efforts can only be directed at prevention. However, in attempting to solve this issue, two major problems arise. Firstly, is the pathogenesis of IM understood and therefore can intervention halt or reverse progression? Secondly, can we diagnose and monitor the condition with any degree of certainty?

**WHAT CAUSES IM AND WHY IS IT IMPORTANT THAT IT IS REVERSIBLE?**

Metaplasia is defined as a potentially reversible change from a fully differentiated cell type to another, which implies adaptation to environmental stimuli, and that embryological commitments can be reversed or erased under certain circumstances. Epidemiological studies have shown that IM in the stomach has a high cancer risk and is therefore defined as a precancerous condition—a clinical state associated with a significantly increased risk of cancer. Dysplasia is a precancerous lesion—a histopathological abnormality in which cancer is more likely to occur than in its apparently normal counterpart. For example, a study carried out in two provinces in China with high and low cancer risks showed that the prevalence of IM was much higher in an area with a high risk for gastric cancer.

"IM in the stomach has a high cancer risk and is therefore defined as a precancerous condition"

Using a gastric cancer risk index, IM was the only criteria associated with the development of intestinal-type gastric cancer in Japan. A long term study concluded that there is an increased risk of gastric cancer in subjects infected with *H pylori*, severe gastric atrophy, body predominant gastritis, or IM. Therefore, if IM is reversible, there are tangible benefits in reduction in gastric cancer risk.

**IF IM IS REVERSIBLE WE NEED TO UNDERSTAND THE PATHOGENESIS**

Of the different types of metaplasia in the stomach, intestinal-type is the most common and it is associated with *H pylori* infection and bile reflux. Experimentally, irradiation induces IM.

*H pylori* and IM

*H pylori* has been implicated as a major cause of IM. Two major studies provide epidemiological evidence for this. In a 10 year follow up of 35 patients with *H pylori*, IM progression was observed in 49% while no IM was seen during this time in non-infected patients. Another study of 2455 individuals showed that IM was present in 43.1% of *H pylori* positive patients compared with 6.2% of uninfected subjects.

"*H pylori* has been implicated as a major cause of IM"

Atrophic gastritis and IM were strongly associated with *H pylori* and not with aging, leading to the conclusion that with a high prevalence of the
precancerous process, mostly by increasing the rate of regression of cancer precursor lesions.\textsuperscript{22}

**Molecular events**

At the molecular level, the sequence of events is under investigation. Microsatellite instability (MSI) is a genetic anomaly in tumours and identified when alleles of novel sizes are detected in microsatellite sequences derived from cancer DNA that are not present in normal tissues of the same individual. These can be detected in IM and the progressive accumulation of MSI in areas of IM may contribute to gastric cancer development.\textsuperscript{23} MSI can be shown to be due to epigenetic silencing of the hMLH1 gene caused by hypermethylation of a CpG island in the promoter region and was found recently to be an important cause of mismatch repair deficiency in sporadic gastric cancer.\textsuperscript{24} Cyclins and cyclin dependent kinase inhibitors play a crucial role in the control of cell cycle transitions. Enhanced expression of cyclin D2 and reduced expression of p27 have been implicated in the pathogenesis of cancer, and over expression of cyclin D2 and reduced expression of p27 are closely linked to \textit{H pylori} associated IM. Eradication of \textit{H pylori} infection reverses the aberrant expression of cyclin D2 and p27 in IM.\textsuperscript{25} These are potential areas for interventional strategies.

“Expression of CDX2 may trigger the initiation and development of IM in the stomach”

In the gastrointestinal tract, homeobox genes regulate the renewal of epithelium at given locations. CDX1 and CDX2 genes are intestinal transcription factors that regulate proliferation and differentiation of intestinal epithelial cells and the CDX1/2 protein is predominantly expressed in the small intestine and colon but not in the normal adult stomach. These genes also have an important role in tumorigenesis.\textsuperscript{26} In IM, expression of CDX2 precedes those of CDX1, sucrase-isomaltase, other intestine specific genes (human defensin 5, alkaline phosphatase), and MUC2 during progression of IM. These findings imply that expression of CDX2 may trigger the initiation and development of IM in the stomach.\textsuperscript{27}

“What switches on CDX1/2 genes in the stomach? The key here is possibly mesenchymal alteration.” The inflammatory response to \textit{H pylori} is also sited in mesenchyme and therefore if this stimulus is removed do these genes switch off? In a recent study from Japan, CDX2 expression in the gastric mucosa was found in patients with chronic gastritis and closely associated with IM.\textsuperscript{28} However, CDX2 expression in IM or gastric epithelial cells did not disappear after eradication of \textit{H pylori}. However, this study examined expression of CDX2 only one year after eradication and may be too short a time course to assess regression of IM, emphasising that this is a slow process. Although neutrophils clear soon after eradication therapy, chronic gastritis and lymphoid aggregates persist at least up to one year\textsuperscript{29} and long term studies are needed to evaluate regression of IM in relation to the chronic inflammatory response.

**HOWEVER, A MAJOR PROBLEM IN DETERMINING IF IM IS REVERSIBLE IS SAMPLING**

**Diagnosis: is IM identifiable at endoscopy?**

IM is recognisable if it is extensive and the endoscopist is experienced. Biopsy should therefore be from sites that show the typical appearance of whitish plaques, patches, or homogeneous discolouration. The accuracy of endoscopic diagnosis in IM was shown to be 71.3% in a study from Taipei.\textsuperscript{30} Another endoscopic method of evaluation is dye endoscopy using methylene blue (methylthioninium chloride). This technique, although described, is not in widespread use. A Japanese study showed it was valuable in assessing
regression of IM\textsuperscript{3} but it is doubtful that time constraints of endoscopists allow this detailed type of examination.

**Diagnosis: where to biopsy?**

Sampling errors also beleaguer the histological diagnosis of IM but with the advent of more powerful endoscopes, this problem may resolve. In routine practice, where should biopsies be taken? The Sydney system for grading gastritis provides practical guidelines for optimal biopsy sampling of the stomach, visual analogue scales for grading histopathological features, and formulation of a comprehensive standardised diagnosis.\textsuperscript{6} A large study from Houston showed that IM was missed in more than 50% of biopsies from "Sydney sites" in patients with confirmed IM on multiple site sampling and concluded that current and future studies that use the Sydney system as a basis for detecting IM are not likely to be reliable.\textsuperscript{7} Substitute measures of gastric cancer risk include histochemical evaluation of IM.\textsuperscript{8}

To identify IM requires careful endoscopic evaluation of "risk" areas (that is, the lesser curve) and assessment of gastric cancer risk. IM can be identified as simple histological features such as glandular crowding, flat or depressed lesions and intestinal features. IM may be associated with a significantly higher risk of atrophic gastritis and IM.\textsuperscript{9}

"It is likely that molecular markers will overtake histochemical evaluation of IM"\textsuperscript{10}

Is typing of IM important? A recent study has shown a high prevalence of type III IM in the general population (4%) and indicates that its role as a precursor of gastric carcinoma may have been overemphasised.\textsuperscript{11} Critical reviews have found many exceptions to given types of IM as precursor lesions of cancer.\textsuperscript{12} It is likely that molecular markers will overtake histochemical evaluation of IM.

To identify IM requires careful endoscopic evaluation of "risk" areas (that is, the lesser curve) and assessment of gastric cancer risk. IM can be identified as simple histological features such as glandular crowding, flat or depressed lesions and intestinal features. IM may be associated with a significantly higher risk of atrophic gastritis and IM.\textsuperscript{9}

**CONCLUSIONS**

In the long term, with follow up of at least five years, there is epidemiological evidence that IM may be reversible although a combination of antioxidant agents and eradication of H pylori may be necessary to achieve this. The pathogenesis of IM is currently being elucidated and it is likely that a combination of bacterial, host, and environmental factors will be shown to lead to IM. There are few studies on the role of acid and/or bile and the pathogenesis of IM—this may be a productive area for future research. IM has widespread implications as metaplasia precedes dysplasia and cancer in many tumours. IM can be elusive to sample unless careful endoscopic evaluation is carried out. In assessing gastric cancer risk, histochromic typng of IM will most probably be replaced by molecular markers although neither of these at present provides a better index than histologc scores of gastric antral and body mucosa and the presence of IM.

**REFERENCES**

Is intestinal metaplasia of the stomach reversible?

M M Walker

_Gut_ 2003 52: 1-4
doi: 10.1136/gut.52.1.1

Updated information and services can be found at:
http://gut.bmj.com/content/52/1/1.1

These include:

**References**
This article cites 37 articles, 6 of which you can access for free at:
http://gut.bmj.com/content/52/1/1.1#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Pancreatic cancer (660)
- Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/